Multisystem regulation of reward and addiction: beyond the dopaminergic system

Addiction to illicit drugs remains a major global health challenge that requires integrative efforts across neuroscience, psychiatry, and pharmacology. A deeper understanding of the neural mechanisms underlying addictive behavior is essential for developing effective and targeted interventions. It is increasingly recognized that addiction cannot be fully explained by dysfunction within dopaminergic circuits alone but rather reflects maladaptive interactions across distributed neuromodulatory and glial networks. Emerging evidence suggests that reward and aversion are better conceptualized within a unified framework of valence processing, in which dopaminergic activity dynamically interacts with orexinergic, histaminergic, endocannabinoid, metabolic, and stress-related systems to shape motivation, reinforcement learning, and affective regulation. Within this expanded architecture, the subventricular tegmental nucleus (SVTg) has recently been identified as a novel brainstem node that may regulate dopaminergic excitability and integrate signals from cortical, limbic, and stress-related circuits. This review synthesizes converging molecular, circuit, and translational evidence supporting a multisystem, network-based model of reward regulation, emphasizing how dysregulation across these systems contributes to addiction vulnerability and related psychiatric phenotypes characterized by compulsivity and impaired valence regulation. Therapeutic advances, including SVTg-targeted neuromodulation, orexin receptor antagonists, histaminergic modulation, and glucagon-like peptide-1 (GLP-1)–based interventions, illustrate the translational potential of this distributed perspective. We argue that future progress will depend on integrating single-cell transcriptomics, real-time neuroimaging, computational psychiatry, and pharmacogenomics to develop mechanistically informed, personalized treatments. Reconceptualizing reward and addiction as emergent properties of distributed brainstem–cortical circuits offers a transformative path toward precision medicine in substance use and related neuropsychiatric disorders.